Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer.
Cancer Res
; 77(24): 6987-6998, 2017 12 15.
Article
en En
| MEDLINE
| ID: mdl-28923856
ABSTRACT
The PPARG gene encoding the nuclear receptor PPARγ is activated in bladder cancer, either directly by gene amplification or mutation, or indirectly by mutation of the RXRA gene, which encodes the heterodimeric partner of PPARγ. Here, we show that activating alterations of PPARG or RXRA lead to a specific gene expression signature in bladder cancers. Reducing PPARG activity, whether by pharmacologic inhibition or genetic ablation, inhibited proliferation of PPARG-activated bladder cancer cells. Our results offer a preclinical proof of concept for PPARG as a candidate therapeutic target in bladder cancer. Cancer Res; 77(24); 6987-98. ©2017 AACR.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Vejiga Urinaria
/
PPAR gamma
/
Terapia Molecular Dirigida
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Cancer Res
Año:
2017
Tipo del documento:
Article